ERBB2 and gastric cancer: Following a clinical trial for HER2-positive gastric cancer and gastro-esophageal junction cancer, the Food and Drug Administration approved the addition of an anti-PD-1 mAb to a conventional first-line treatment with combination chemotherapy and an anti-HER2 mAb [18].